Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 7/20 | 0.55 |
| ▸ | MC4R | P32245 | 1/20 | 0.52 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.48 |
| ▸ | APOL1 | O14791 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | TSPO | P30536 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31006355 | 0.87 | EGFR (0.60) | TACR1MC4RCXCR2EGFR | |
| SCHEMBL22118483 | 0.87 | EGFR (0.60) | TACR1MC4RCXCR2EGFR | |
| SCHEMBL24907068 | 0.80 | APOL1 (0.68) | TACR1CXCR2APOL1CYP2C9EGFR | |
| SCHEMBL7799897 | 0.80 | TSPO (0.64) | TACR1APOL1CYP1A2HPGDCYP2C19 | |
| SCHEMBL6922498 | 0.76 | PPARG (0.66) | TACR1CYP1A2CYP2D6CYP2C9HPGD | |
| SCHEMBL22118392 | 0.74 | APOL1 (0.71) | TACR1MC4RCXCR2APOL1 | |
| SCHEMBL22161381 | 0.74 | APOL1 (0.71) | TACR1MC4RCXCR2APOL1 | |
| SCHEMBL6928281 | 0.74 | TLR8 (0.43) | TACR1MC4RCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6928572 | 0.73 | TACR1 (0.76) | TACR1 | |
| SCHEMBL8216635 | 0.73 | HPGD (0.64) | TACR1CYP1A2CYP2D6CYP2C9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6518273-B1 | 2-aryl indole derivative as antagonists of tachykinins | MERCK SHARP & DOHME LTD. | 2003-02-11 | — | — | US | disclosed |
| US-20010039286-A1 | 2-aryl indole derivatives and their use as therapeutic agents | DINNELL KEVIN (GB) | 2001-11-08 | — | — | US | disclosed |
| WO-2000051984-A1 | 2-ARYL INDOLE DERIVATIVES AS ANTAGONISTS OF TACHYKININS | MERCK SHARP & DOHME LIMITED (GB) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039286-A1 | 2-aryl indole derivatives and their use as therapeutic agents | IDO1, IDO2, CNR2 | TACR1 1285/4885MC4R 372/4885CXCR2 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.